Cellular localization of nucleolin determines the prognosis in cancers: a meta-analysis
Supaporn Yangngam, Jaturawitt Prasopsiri, Phimmada Hatthakarnkul, Suyanee Thongchot, Peti Thuwajit, Pa‐thai Yenchitsomanus, Joanne Edwards, Chanitra Thuwajit
Abstract
Abstract Nucleolin (NCL) is a multifunctional protein expressed in the nucleus, cytoplasm, and cell membrane. Overexpression of NCL has a controversial role as a poor prognostic marker in cancers. In this study, a meta-analysis was performed to evaluate the prognostic value of NCL in different subcellular localizations (cytoplasmic (CyNCL) and nuclear (NuNCL)) across a range of cancers. PubMed was searched for relevant publications. Data were extracted and analyzed from 12 studies involving 1221 patients with eight cancer types. The results revealed high total NCL was significantly associated with poor overall survival (OS) (HR = 2.85 (1.94, 4.91), p < 0.00001, I 2 = 59%) and short disease-free survival (DFS) (HR = 3.57 (2.76, 4.62), p < 0.00001, I 2 = 2%). High CyNCL was significantly associated with poor OS (HR = 4.32 (3.01, 6.19), p < 0.00001, I 2 = 0%) and short DFS (HR = 3.00 (2.17, 4.15), p < 0.00001, I 2 = 0%). In contrast, high NuNCL correlated with increased patient OS (HR = 0.42 (0.20, 0.86), p = 0.02, I 2 = 66%), with no significant correlation to DFS observed (HR = 0.46 (0.19, 1.14), p = 0.09, I 2 = 57%). This study supports the role of subcellular NCL as a poor prognostic cancer biomarker.